Operating Segments

12 Months Ended

Dec. 31, 2021

Operating Segments

Operating Segments

Note 12. Operating Segments

The Company maintains two active operating segments: Specialized BioTherapeutics and Public Health Solutions. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	For the Years Ended
	December 31,
	2021		2020
Revenues
Specialized BioTherapeutics	$	—	$	117,369
Public Health Solutions		824,268		2,242,078
Total	$	824,268	$	2,359,447
Loss from Operations
Specialized BioTherapeutics	$	(7,280,936)	$	(13,610,715)
Public Health Solutions		(647,600)		(85,417)
Corporate		(5,212,349)		(4,890,375)
Total	$	(13,140,885)	$	(18,586,507)
Amortization and Depreciation Expense
Specialized BioTherapeutics	$	7,804	$	11,839
Public Health Solutions		16,801		21,672
Corporate		9,556		28,861
Total	$	34,161	$	62,372
Other (Expense)/Income, Net
Specialized BioTherapeutics	$	135,409	$	71,974
Corporate		(410,239)		(10,882)
Total	$	(274,830)	$	61,092
Share-Based Compensation
Specialized BioTherapeutics	$	136,594	$	148,107
Public Health Solutions		21,884		47,453
Corporate		203,081		214,373
Total	$	361,559	$	409,933

	As of December 31,
	2021		2020
Identifiable Assets
Specialized BioTherapeutics	$	128,645	$	176,447
Public Health Solutions		146,296		147,784
Corporate		26,594,986		19,567,004
Total	$	26,869,927	$	19,891,235